Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial

Open access

Abstract

Background Preterm delivery during pregnancy (<37 weeks' gestation) is a leading cause of perinatal mortality and morbidity. Treating bacterial vaginosis during pregnancy can reduce poor outcomes, such as preterm birth. We aimed to investigate whether treatment of bacterial vaginosis decreases late miscarriages or spontaneous very preterm birth.Methods PREMEVA was a double-blind randomised controlled trial done in 40 French centres. Women aged 18 years or older with bacterial vaginosis and low-risk pregnancy were eligible for inclusion and were randomly assigned (2:1) to three parallel groups: single-course or triple-course 300 mg clindamycin twice-daily for 4 days, or placebo. Women with high-risk pregnancy outcomes were eligible for inclusion in a high-risk subtrial and were randomly assigned (1:1) to either single-course or triple-course clindamycin. The primary outcome was a composite of late miscarriage (16-21 weeks) or spontaneous very preterm birth (22-32 weeks), which we assessed in all patients with delivery data (modified intention to treat). Adverse events were systematically reported. This study is registered with ClinicalTrials.gov, number NCT00642980.Findings Between April 1, 2006, and June 30, 2011, we screened 84 530 pregnant women before 14 weeks' gestation. 5630 had bacterial vaginosis, of whom 3105 were randomly assigned to groups in the low-risk trial (n=943 to receive single-course clindamycin, n=968 to receive triple-course clindamycin, and n=958 to receive placebo) or high-risk subtrial (n=122 to receive single-course clindamycin and n=114 to receive triple-course clindamycin). In 2869 low-risk pregnancies, the primary outcome occurred in 22 (1·2%) of 1904 participants receiving clindamycin and 10 (1·0%) of 956 participants receiving placebo (relative risk [RR] 1·10, 95% CI 0·53-2·32; p=0·82). In 236 high-risk pregnancies, the primary outcome occurred in 5 (4·4%) participants in the triple-course clindamycin group and 8 (6·0%) participants in the single-course clindamycin group (RR 0·67, 95% CI 0·23-2·00; p=0·47). In the low-risk trial, adverse events were more common in the clindamycin groups than in the placebo group (58 [3·0%] of 1904 vs 12 [1·3%] of 956; p=0·0035). The most commonly reported adverse event was diarrhoea (30 [1·6%] in the clindamycin groups vs 4 [0·4%] in the placebo group; p=0·0071); abdominal pain was also observed in the clindamycin groups (9 [0·6%] participants) versus none in the placebo group (p=0·034). No severe adverse event was reported in any group. Adverse fetal and neonatal outcomes did not differ significantly between groups in the high-risk subtrial.Interpretation Systematic screening and subsequent treatment for bacterial vaginosis in women with low-risk pregnancies shows no evidence of risk reduction of late miscarriage or spontaneous very preterm birth. Use of antibiotics to prevent preterm delivery in this patient population should be reconsidered.Funding French Ministry of Health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)31617-9

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. Nugent, 1991, Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation, J Clin Microbiol, 29, 297, 10.1128/JCM.29.2.297-301.1991 · DOI · Paper page

Cited by

See all 152

Metadata

Authors
Subtil, D., Brabant, G., Tilloy, E., Devos, P., Canis, F., Fruchart, A., Bissinger, M.-C., Dugimont, J.-C., Nolf, C., Hacot, C., Gautier, S., Chantrel, J., Jousse, M., Desseauve, D., Plennevaux, J. L., Delaeter, C., Deghilage, S., Personne, A., Joyez, E., Guinard, E., Kipnis, E., Faure, K., Grandbastien, B., Ancel, P.-Y., Goffinet, F., & Dessein, R.
Affiliations
  • Université de Lille (FR)
  • Groupe Hospitalier de l'Institut Catholique de Lille (FR)
  • Centre Hospitalier de Valenciennes (FR)
  • Centre Hospitalier Universitaire de Lille (FR)
  • Centre Hospitalier Universitaire de Poitiers (FR)
  • Centre Hospitalier d'Arras (FR)
  • Inserm (FR)
Corresponding author
Dessein, Rodrigue
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-11
Volume
392
Issue
10160
Pages
2171-2179
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2896317272
Cited by
152
References
26
Citations by year
2026: 7 · 2025: 13 · 2024: 14 · 2023: 22 · 2022: 12 · 2021: 40 · 2020: 26 · 2019: 12 · 2018: 4
FWCI
16.55
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
  • Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
Funders
French Ministry of Health (PHRC 2004 CP04156)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Obstetrics and Gynecology › Preterm Birth and Chorioamnionitis
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and Maternal Infections
Keywords
bacterial vaginosis, pregnancy, clindamycin, preterm birth, late miscarriage, very preterm birth, antibiotic therapy, low-risk pregnancy, high-risk pregnancy, perinatal outcomes, vaginal microbiota, vaginal discharge
MeSH terms
Abortion, Spontaneous, Adult, Anti-Bacterial Agents, Clindamycin, Double-Blind Method, Female, Humans, Pregnancy, Pregnancy Complications, Infectious, Pregnancy Outcome, Vaginosis, Bacterial, Premature Birth

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31617-9
The paper
Subtil, D., Brabant, G., Tilloy, E., Devos, P., Canis, F., Fruchart, A., Bissinger, M.-C., Dugimont, J.-C., Nolf, C., Hacot, C., Gautier, S., Chantrel, J., Jousse, M., Desseauve, D., Plennevaux, J. L., Delaeter, C., Deghilage, S., Personne, A., Joyez, E., . . . Dessein, R. (2018). Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)31617-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.